1[1]van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer-cell lines. Br J Cancer,1999,80(7)∶981-990.
2[2]Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase Ⅱ study. J Clin Oncol,1994,12(9)∶1821-1826.
3[3]Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer : A multicentre, extended phase Ⅱ study. Eur J Cancer,1996,32A(2)∶243-248.
4[4]Noble S, Faulds D. Management of advanced non-small-cell lung cancer. The potential role of gemcitabine. Heath Outcomes,1999,5(3)∶167-169.
1[1]Manegold C, Zatloukal P, Krejcy K, et al. Gemcitabine in non-small-cell lung cancer[J]. Invest New Drugs,2000,18(1):29-42.
2[2]Merimsky O, Wigler N, Greif Y, et al. Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small-cell lung cancer: a phase Ⅱ study[J]. Anticancer Drugs,2000,11(2):117-121.
3[3]Sandler AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2000,18(1):122-130.
4[4]Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,1999,17(1):12-18.
5[5]Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase Ⅲ study of the Italian Lung Cancer Project[J]. J Clin Oncol1999,17(11):3522-3530.
6[6]Schiller J, Harrington D, Sandler A, et al. A randomized phase III trial of fourchemotherapy regimens in advanced non-samll cell lung cancer (NSCLC)[J]. Am Soc Clin Oncol,2000,19:1-1.
7[7]Kroep JR, Peters GJ, van Moorsel CJA, et al. Gemcitabine-cisplatin: A schedule finding study[J]. Ann Oncol,1999,10(12):1503-1510.
8[8]Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer[J]. J Clin Oncol,1999,17(7):2190-2197.
9[9]Sorensen JB, Stenbygaard LE, Dombernowsky P, et al. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung Cancer[J]. Ann Oncol1999,10(9):1043-1049.
10[10]Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase Ⅱ trial[J]. J Clin Oncol,1999,17(3):914-920.
1Wan Moorsel C J, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small lung cancer-cell lines [J]. Br J Cancer. 1999.80 (7) :981 - 990.
2Johnson DH. Gemcilabine for the trealmenl of non-small-cell lung cancer [J]. Oncology ( Hunling ). 2001 , 15 ( Suppl6 ): 33 -39.
